Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients (LAM-RAPA)

This study has been completed.
French Innovative Leukemia Organisation
Information provided by:
University Hospital, Toulouse Identifier:
First received: September 9, 2005
Last updated: June 19, 2008
Last verified: June 2008
These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Condition Intervention Phase
Acute Myeloid Leukemia
Drug: rapamycin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)

Resource links provided by NLM:

Further study details as provided by University Hospital, Toulouse:

Primary Outcome Measures:
  • response rate [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • tolerability [ Designated as safety issue: Yes ]
  • bioclinical markers of response [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: June 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: rapamycin
    Other Name: RAPAMUNE
Detailed Description:
Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 60 y.
  • Informed consent
  • de novo or secondary LAM(CML excluded) not elligible for intensive chemotherapy.
  • Previously untreated

Exclusion Criteria:

  • Renal impairment (serum creatinin >2N)
  • Hepatic impairment (TGO ou TGP > 5N), une cholestase (Phosphatases Alcalines or gamma-GT > 5N),bilirubin > 3N

    • Blast crisis CML
    • Acute Promyelocytic Leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00235560

Service d'Hématologie, CHU
Angers, France, 49100
Service d'Hématologie, Hôpital Jean Minjoz
BESANçON, France, 25000
Service d'Hématologie CHU Purpan
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Toulouse
French Innovative Leukemia Organisation
Principal Investigator: RECHER Christian CHU Toulouse
  More Information

Responsible Party: LLAU Marie-Elise, University Hospital Toulouse Identifier: NCT00235560     History of Changes
Other Study ID Numbers: 0402008  GOELAMS  PHRC 
Study First Received: September 9, 2005
Last Updated: June 19, 2008
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Toulouse:
Elderly patients not eligible for intensive chemotherapy

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 27, 2016